1. Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed 
Naruo Yoshimura, MD, PhD, Kyoichi Okishio, MD, PhD, Shigeki Mitsuoka, MD, PhD, Tatsuo Kimura, MD, PhD, Tomoya Kawaguchi, MD, PhD, Masaji Kobayashi, MD, PhD, Tomonori Hirashima, MD, PhD, Haruko Daga, MD, PhD, Koji Takeda, MD, PhD, Kazuto Hirata, MD, PhD, Shinzoh Kudoh, MD, PhD 
Journal of Thoracic Oncology 
Volume 8, Issue 1, Pages (January 2013)
DOI: /JTO.0b013e bfb
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
A, Kaplan–Meier estimate of PFS for all patients. The median PFS was 7.0 months (95% CI, 6.2–7.8 months). The 6-month and 1-year progression-free rates were 56.5% and 19.4%, respectively. B, Kaplan–Meier estimate of OS for all patients. The MST was 11.4 months (95% CI, 9.4–13.5 months). The 6-month and 1-year OS rates were 75.5% and 50.0%, respectively. The symbols (I) represent censored patients. PFS, progression-free survival; OS, overall survival; MST, median survival time; CI, confidence interval.
Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e bfb)
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions